Ticker

BlackRock Inc. acquired a new stake in shares of Prime Medicine, Inc. (NASDAQ: PRME) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,602,041 shares of the company's stock, valued at approximately $35,432,000. BlackRock Inc. owned about 5.32% of Prime Medicine

Prime Medicine trades at a $548M valuation, significantly undervaluing its broad, potentially best-in-class gene-editing pipeline. PRME's therapies target five indications across liver, lung, and immunology/oncology, with leading preclinical efficacy and multi-billion-dollar addressable markets. Recent IND/CTA clearances, RMAT designation, and patent wins highlight PRME's clinical and strategic momentum despite a…

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.24 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.41 per share a year ago.

Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America and Europe -- -- Initial clinical data expected in 2027 -- CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company…